Shoreline Biosciences

Shoreline Biosciences is a private, pre-clinical stage biotech founded in 2020 and headquartered in San Diego, CA. The company is pioneering a platform for developing homogeneous, scalable, 'off-the-shelf' cellular immunotherapies using engineered iPSC-derived natural killer cells and macrophages. Its approach aims to overcome key limitations of autologous cell therapies, such as manufacturing complexity, high cost, and product variability. Shoreline is building a pipeline of candidates targeting cancer and other serious diseases, positioning itself in the competitive but high-potential allogeneic cell therapy space.

Integrated platform for developing off-the-shelf, iPSC-derived natural killer cell (iNK) and macrophage (iMACs) immunotherapies, utilizing proprietary iPSC engineering, differentiation, and genetic modification technologies.

Shoreline competes in the rapidly evolving allogeneic cell therapy space against companies like Fate Therapeutics and Century Therapeutics (iPSC-derived NK/T cells), Nkarta (donor-derived NK cells), and others developing engineered immune cells. Differentiation hinges on its specific engineering strategies, macrophage platform, and ability to demonstrate clinical superiority.